





A unit of Artemis Medicare Services Ltd

August 5, 2025

Listing Department, National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051

NSE Symbol: ARTEMISMED

Listing Department, **BSE Limited**

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai – 400 001

Scrip Code: 542919

Dear Sir/Madam.

Sub: Outcome of Board Meeting held on August 5, 2025

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at its meeting held today, inter-alia, considered and approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the guarter ended June 30, 2025.

Pursuant to Regulation 33 of SEBI Listing Regulations, please find enclosed herewith the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2025 and limited review reports for the said period issued by the Statutory Auditors of the Company.

In terms of Regulation 47 of SEBI Listing Regulations, the extract of the Un-audited Consolidated Financial Results for the quarter ended June 30, 2025, along with the Quick Response (QR) code and the details of the webpage where the complete financial results are accessible, shall be published in the newspapers.

The full format of the financial results shall be available on the website of the Stock Exchanges where equity shares of the Company are listed i.e. www.nseindia.com and www.bseindia.com and on Company's website www.artemishospitals.com.

The meeting of the Board of Directors commenced at 3:15 PM and concluded at 4:25 PM.

You are requested to take the same on your record.

Thanking you,

Yours faithfully,

For Artemis Medicare Services Limited

Poonam Makkar **Company Secretary & Compliance Officer**

Encl.: As above













T R Chadha & Co LLP



Independent Auditor's Review Report on Review of Interim Unaudited Standalone Financial Results of Artemis Medicare Services Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To, The Board of Directors Artemis Medicare Services Limited

- 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Artemis Medicare Services Limited** ("the Company") for the quarter ended June 30, 2025, (hereinafter referred to as "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to date ("Listing Regulations").
- 2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

dha &

NOIDA

For T R Chadha & Co LLP

Chartered Accountants

Firm Registration No.006711N/N500028

Neena Goel

Partner

Membership No. 057986 Place of signature: Noida

Date: August 05, 2025

UDIN: 25057986 BMIKMW6498

ARTEMIS MEDICARE SERVICES LIMITED

CIN: L85110DL2004PLC126414

Registered office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075

Ph.: +91-124-4511111; Email: investor@artemishospitals.com; Website: www.artemishospitals.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(₹in Lacs)

		Quarter ended			Year ended	
200	Particulars	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	
5 No.		(Unaudited)	(Audited) (Refer Note 3)	(Unaudited)	(Audited)	
1.	Income					
	(a) Revenue from Operations	24,979.86	23,480.13	21,689.24	91,326.13	
	(b) Other Income	695.76	1,223.30	438.19	3,291.50	
	Total Income	25,675.62	24,703.43	22,127.43	94,617.63	
2.	Expenses					
	(a) Operative Expenses	15,444.56	14,297.74	13,030.80	55,160.06	
	(b) Purchases of Stock in Trade	*	200	18	5	
	(c) Changes in inventories of Stock in Trade	*		0.54	0.54	
	(d) Employee Benefits Expense	3,730.65	3,799.93	3,465.17	14,371.00	
	(e) Finance Costs	710.92	752.82	769.93	3,048.26	
	(f) Depreciation and Amortization Expense	1,065.99	1,124.82	1,022.29	4,301.80	
	(g) Other Expenses	1,716.79	1,828.40	1,625.09	6,810,51	
	Total Expenses	22,668.91	21,803.71	19,913.82	83,692.17	
3.	Profit before exceptional items and tax (1-2)	3,006.71	2,899.72	2,213.61	10,925.46	
4.	Exceptional Items				- 4	
5.	Profit before tax (3+4)	3,006.71	2,899.72	2,213.61	10,925.46	
6.	Tax Expense:					
	(a) Current Tax	672.82	356.03	463.97	2,111.26	
	(b) Earlier Year Tax	2	20.96	-	20.96	
	(c) Deferred Tax Charge / (Credit)	192.17	202.27	57.98	447.46	
	Total Tax Expense	864.99	579.26	521.95	2,579.68	
7.	Net Profit after tax (5-6)	2,141.72	2,320.46	1,691.66	8,345.78	
8.	Other comprehensive income / (Loss)					
	Items that will not be reclassified to profit or loss					
	(a) Remeasurement gain/(loss) of defined employee benefit plans	(19.79)	50.01	(24.89)	(79.15	
	(b) Income Tax relating to items that will not be reclassified to profit or loss	4.98	(12.59)	6.27	19.92	
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	11.01	12.71	12.71	50.83	
	Net Other comprehensive income / (Loss)	(3.80)	50.13	(5.91)	(8.40)	
9.	Total comprehensive income (7+8)	2,137.92	2,370.59	1,685.75	8,337.38	
10.	Paid up Equity Share Capital (Face value Re. 1/- each)	1,389.32	1,376.02	1,369.16	1,376.02	
11.	Other Equity (Excluding Revaluation Reserves)				75,954.72	
12.	Earning per Equity Share (Face value Re. 1/- each)					
	(a) Basic	1.36*	1.48*	1.16*	5.42	
	(b) Diluted	1.35*	1.47*	1.14*	5.36	

^{*} Not annualised





arkar karmer

Notes:

- 1. The above unaudited standalone financial results for the quarter ended June 30, 2025 (financial results) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on August 05, 2025. The statutory auditors, T R Chadha & Co LLP have expressed an unmodified conclusion on the aforesaid financial results.
- 2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the other recognised accounting practices and policies to the extent applicable and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3. The results for the quarter ended March 31, 2025, are the balancing figures between audited figures in respect of full financial year ended March 31, 2025 and published and unaudited results for the nine month period ended December 31, 2024.

4. Segment Reporting:

The Company's operation predominantly comprises providing Healthcare services to patients. As per Ind AS 108 and our internal structure and information mechanisms, the Company has only one reportable business segment, i.e., "Healthcare Services".

Geographical information

Geographical information analyses the Company's revenue by the country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region	Revenue from Operations				
·	C	Quarter ended			
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	
India	17,936.64	16,233.11	16,329.24	65,893.47	
Outside India	7,043.22	7,247.02	5,360.00	25,432.66	
Total	24,979.86	23,480.13	21,689.24	91,326.13	
Region	Carrying amount of Non-Current Assets				
			Year ended		
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	
India	79,690.69	79,363.07	77,957.49	79,363.07	
Outside India	•		-	7	
Total	79,690.69	79,363.07	77,957.49	79,363.07	

- 5. During the quarter ended June 30, 2025, the Company has issued 13,30,000 number of equity shares, each fully paid up at ₹1/- per share to it's Managing Director pursuant to Artemis Medicare Management Stock Option Plan - 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the Company.
- 6. During the quarter, the Company entered into a binding Memorandum of Understanding (MoU) with Dr. Vidyasagar Kaushalya Devi Memorial Health Centre ("the Society") to secure the right to enter into a Medical Services Agreement (MSA), subject to the Society fulfilling specified conditions outlined in the MoU. In connection with this arrangement, the Company has paid an advance deposit of ₹54 crores.
- 7. The previous period's/year's figures have been regrouped/reclassified wherever necessary to correspond with the current period/year classification/disclosures.

Place : Gurugram

dha & C

Date : August 05, 2025

For and on behalf of the Board of Directors of Artemis Medicare Services Limited

Oukar Kenny

Onkar Kanwar Chairman

DIN: 00058921



TR Chadha & Co LLP



Independent Auditor's Review Report on Review of Interim Unaudited Consolidated Financial Results of Artemis Medicare Services Limited Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Artemis Medicare Services Limited

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Artemis Medicare Services Limited ('the Holding Company') and its subsidiary (the holding Company and its subsidiary together referred to as 'the Group') for the quarter ended June 30, 2025, (hereinafter referred to as "Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended to date ("Listing Regulations").
- 2. The Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Holding Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with circular issued by the SEBI under Regulations 33(8) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the results of the following entities:
 - a. Artemis Medicare Service Limited, the Holding Company
 - b. Artemis Cardiac Care Private Limited, a Subsidiary Company
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of Listing Regulations (as amended) including the manner in which it is to be disclosed, or that it contains any



TR Chadha & Co LLP



Other Matters

6. The accompanying Statements include the unaudited interim financial results/ statement and other financial information, in respect of the subsidiary company i.e., Artemis Cardiac Care Private Limited, whose unaudited interim financial results/ statements include total revenue of ₹518.09 lakhs, total Net Loss after Tax of ₹23.24 lakhs, total comprehensive loss of ₹23.60 lakhs, for the quarter ended on June 30, 2025, as considered in the Statement.

These unaudited interim financial statements and other financial information have been reviewed by another firm of Chartered Accountants whose Review Report, vide which they have issued an unmodified conclusion, have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

7. Our conclusion on the Statement is not modified in this matter.

dha &

NOIDA

red Accou

For T R Chadha & Co LLP

Chartered Accountants

Firm Registration No.006711N/N500028

Neena Goel

Neevot

Partner

Membership No. 057986 Place of signature: Noida

Date: August 05, 2025

UDIN: 25057986 BMIKMX6315

ARTEMIS MEDICARE SERVICES LIMITED

CIN: L85110DL2004PLC126414

Registered office: Plot No.14, Sector 20, Dwarka, South West Delhi, Delhi- 110075 Ph.: +91-124-4511111; Email: investor@artemishospitals.com; Website: www.artemishospitals.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(₹ in Lacs)

		(₹ in Lacs				
	. Particulars	Quarter ended			Year ended	
S No.		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	
		(Unaudited)	(Audited) (Refer Note 3)	(Unaudited)	(Audited)	
1.	Income					
	(a) Revenue from Operations	25,496.09	23,990.01	22,320.38	93,691.67	
	(b) Other Income	692.79	1,234.50	440.38	3,298.59	
	Total Income	26,188.88	25,224.51	22,760.76	96,990.26	
2.	Expenses					
	(a) Operative Expenses	15,726.73	14,591.47	13,395.30	56,521.05	
	(b) Purchases of Stock in Trade					
	(c) Changes in inventories of Stock in Trade			0.54	0.54	
	(d) Employee Benefits Expense	3,840.09	3,914.30	3,588.51	14,837.26	
	(e) Finance Costs	738.18	783.22	813.39	3,194.48	
	(f) Depreciation and Amortization Expense	1,115.63	1,174.28	1,079.93	4,516.49	
	(g) Other Expenses	1,789.81	1,894.82	1,719.18	7,153.86	
	Total Expenses	23,210.44	22,358.09	20,596.85	86,223.68	
3.	Profit before exceptional items and tax (1-2)	2,978.44	2,866.42	2,163.91	10,766.58	
4.	Exceptional Items					
5.	Profit before tax (3+4)	2,978.44	2,866.42	2,163.91	10,766.58	
6.	Tax Expense:					
	(a) Current Tax	672.82	356.03	463.97	2,111.26	
	(b) Earlier Year Tax	-	20.96		20.96	
	(c) Deferred Tax Charge / (Credit)	185.87	197.04	47.51	416.74	
	Total Tax Expense	858.69	574.03	511.48	2,548.96	
7.	Net Profit after tax (5-6)	2,119.75	2,292.39	1,652.43	8,217.62	
8.	Other comprehensive income / (Loss)					
	Items that will not be reclassified to profit or loss					
	(a) Remeasurement gain/(loss) of defined employee benefit plans	(20.27)	50.11	(24.99)	(81.08)	
	(b) Income Tax relating to items that will not be reclassified to profit or loss	5.10	(12.61)	6.29	20.41	
	(c) Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss	11.01	12.71	12.71	50.83	
	Net Other comprehensive income / (Loss)	(4.16)	50.21	(5.99)	(9.84)	
9.	Total comprehensive income (7+8)	2,115.59	2,342.60	1,646.44	8,207.78	
10.	Profit / (Loss) attributable to :					
	Shareholders of the Company	2,127.90	2,302.92	1,666.68	8,262.58	
	Non-Controlling Interest	(8.13)	(10.51)	(14.25)	(44.96)	
11.	Total Comprehensive Income / (Loss) attributable to :					
	Shareholders of the Company	2,123.85	2,353.09	1,660.71	8.253.24	
	Non-Controlling Interest	(8.26)	(10.49)	(14.27)	(45.46)	
12.	Paid up Equity Share Capital (Face value Re. 1/- each)	1,389.32	1,376.02	1,369.16	1,376.02	
13.	Other Equity (Excluding Revaluation Reserves)			-	75,542.52	
14.	Earning per Equity Share (Face value Re. 1/- each)					
	(a) Basic	1.35*	1.47*	1.14*	5.37	
	(b) Diluted	1.35*	1.45*	1.12*	5.31	

^{*} Not annualised





Onekar kannie

Notes:-

- 1. The above unaudited Consolidated financial results of Artemis Medicare Services Limited (the Company) and one Subsidiary Company (together referred as 'the Group') for the quarter ended June 30, 2025, have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on August 05, 2025. The statutory auditors, T R Chadha & Co LLP have expressed an unmodified conclusion on the aforesaid financial results.
- 2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS), as prescribed under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and the other recognised accounting practices and policies to the extent applicable and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3. The results for the quarter ended March 31, 2025, are the balancing figures between audited figures in respect of full financial year ended March 31, 2025 and published and unaudited results for the nine month period ended December 31, 2024.

4. Segment Reporting:

The Group's operation predominantly comprises providing Healthcare services to patients. As per Ind AS 108 and our internal structure and information mechanisms, the Group has only one reportable business segment, i.e., "Healthcare Services".

Geographical information

Geographical information analyses the Group's revenue by the Group's country of domicile (i.e. India) and other countries. In presenting the geographical information, segment revenue has been based on the geographical location of the customers.

Region		Revenue from Operations				
	C	Quarter ended				
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-2		
India	18,452.87	16,742.99	16,960.38	68,259.01		
Outside India	7,043.22	7,247.02	5,360.00	25,432.66		
Total	25,496.09	23,990.01	22,320.38	93,691.67		
Region	Carrying amount of Non-Current Assets					
	C	Quarter ended		Year ended		
tside India tal Region lia tside India	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25		
India	81,462.56	81,142.92	80,199.37	81,142.92		
Outside India	-	-	- 1			
Total	81,462.56	81,142.92	80,199.37	81,142.92		

- 5. During the quarter ended June 30, 2025, the Parent Company has issued 13,30,000 number of equity shares, each fully paid up at ₹1/- per share to it's Managing Director pursuant to Artemis Medicare Management Stock Option Plan 2021 (the Plan), which have been duly listed in the respective Stock Exchanges, ranking pari passu with the existing equity shares of the parent Company.
- 6. During the quarter, the Parent Company entered into a binding Memorandum of Understanding (MoU) with Dr. Vidyasagar Kaushalya Devi Memorial Health Centre ("the Society") to secure the right to enter into a Medical Services Agreement (MSA), subject to the Society fulfilling specified conditions outlined in the MoU. In connection with this arrangement, the Company has paid an advance deposit of ₹54 crores.
- 7. The previous period's/year's figures have been regrouped/reclassified wherever necessary to correspond with the current period/year classification/disclosures.

Place : Gurugram Date : August 05, 2025

dha & C

red Acc

wedicate Colvicos

For and on behalf of the Board of Directors of Artemis Medicare Services Limited

Onkar Kanwar Chairman

DIN: 00058941